ClinicalTrials.gg
RecruitingNCT06950515RESSOURCEUpdated Nov 9, 2026

General Anesthesia vs Conscious Sedation for Radial Endobronchial Ultrasound

An interventional study of Peripheral EBUS under Concious sedation and Peripheral EBUS under General Anesthesia in Lung Cancers and Peripheral Pulmonary Nodules, sponsored by Institut universitaire de cardiologie et de pneumologie de Québec, University Laval. Recruiting at 4 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Institut universitaire de cardiologie et de pneumologie de Québec, University Laval · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 1 month later.
Updated Nov 9, 2026First sites in Germany, Greece and SpainEligibility revised+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
306
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 383 studies in Lung Neoplasms with a site in Canada — 66 open to participants now, 99 under way, 26 of them phase 3. Lung Neoplasms · Canada.

Planned enrollment
73rd of 315
306 · median 100
Started
2025
with 18 others
No phase
83 of 383
13 open now
Primary completion
2027-08
later than 42 of 98 live
Registered
364th of 383
by date

Among the 383 studies in Lung Neoplasms with a site in Canada, this one is the 73rd largest by planned enrollment of the 315 interventional ones that give a count, is one of 19 that started in 2025, is one of 83 with no phase, reaches primary completion later than 42 of the 98 other live ones, and was the 364th registered.

Lung Neoplasms

5,434 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

66 of the 383 studies in Lung Neoplasms with a site in Canada are open now. Recruiting first, the newest first:

60 more — sign in →

All 66 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 383 studies in Lung Neoplasms with a site in Canada, or all of them as a file.
02

Study summary

The endoscopic investigation of lung lesions is experiencing significant growth with the increasing number of lung cancer screening programs. Peripheral endobronchial ultrasound (pEBUS) is the most widely used endoscopic technique in the investigation of peripheral pulmonary lesions (PPL). It is performed in relatively equal proportions under conscious sedation and general anesthesia by interventional pulmonologists throughout the world. Users of conscious sedation justify themselves by the fewer resources consumed and the absence of demonstration of a superior diagnostic yield of general anesthesia while users of general anesthesia claim diagnostic yield and comfort for the patient are superior with their approach. Our main objective is to compare the diagnostic yield of pEBUS under general anesthesia to that obtained under conscious sedation.

Read the detailed description

This is a multicenter randomized clinical trial to compare the diagnostic yield of pEBUS under general anesthesia and conscious sedation in the context of the investigation of peripheral pulmonary lesions.

Participants will be recruited prospectively. Potential participants will be identified during the screening of procedure requisitions by the interventional pulmonology team. The participant will then be approached by the physician to obtain their consent to the procedure and the study during a first visit, which can be face-to-face, by phone or by telemedicine. During this visit, the research protocol and the risks involved will be explained to the participant by the physician to obtain their free and informed consent for both. After verifying eligibility criteria and obtaining consent, participants will be included in the study and randomized. Participants will be randomized to the type of sedation for the procedure (general anesthesia or conscious sedation) and the procedure can, then, be scheduled with the sedation mode assigned during randomization. During a second visit, which may take place on the same day as the first, the participant will undergo pEBUS under conscious sedation or general anesthesia depending on the group to which he was randomized. Prior to discharge, the participant's comfort questionnaires will be administered. One month after the procedure, the research team will consult the participant's medical record to review the results of the samples taken during the examination and to ensure that the participant have not suffered any late complications following the procedure. The patient will be instructed to contact the research team again if they believe they have had a late complication. The record will subsequently be reviewed at 1 and 2 years if the procedure is not diagnostic to validate the final clinical diagnosis of the treating team. Communication of the results and further treatment of the patient will be the responsibility of the referring physician or his team and not that of the research team.

In both groups, an ultrathin or thin bronchoscope (eg.: MP109 or P180/190 bronchosscope, Olympus, Tokyo, Japan) and a radial EBUS probe (eg.: UM-S20-17S or 20R-3, Olympus, Tokyo, Japan) will be used. A guidesheath can be used when performing pEBUS procedures with a thin bronchoscope but not when using an ultrathin. Each center will determine before beginning recruitment for the study whether a thin bronchoscope with or without guidesheath or an ultrathin bronchoscope without guidesheat will be used.

Centers must systematically use the same type of bronchoscope and guidesheath for all participants recruited according to their predetermined conduct. Minimally, a wash, forceps and a brush will be performed to sample lesion. Forceps biopsies will be taken until five macroscopically visible specimens are obtained, up to a maximum of 8 attempts. A single brushing as well as a cytological bronchoalveolar washing, of at least 50ml, will be carried out. At the discretion of the center, a peripheral needle for fine needle aspiration (FNA) may also be used (eg. Periview, Olympus, Tokyo, Japan). If used, 3 passes will be performed, but additional passes are permitted at the discretion of the endoscopist and depending on the material obtained macroscopically. Each center will determine before beginning recruitment for the study whether or not it will use FNA. Centers must systematically use it or not, for all participants recruited according to local predetermined sampling protocol.

A 1.1mm cryoprobe (Erbe, Tuebingen, Germany) can also be used at the discretion of the endoscopist. Cryobiopsies do not have to be performed or not performed in all participants in a center, in contrast to FNA, and can be used at the discretion of the bronchoscopist. Cryobiopsies may be used systematically in both arms of the study in a participating center. This latitude with the use of cryobiopsies is explained by the higher risk associated with cryobiopsies and the strong conviction of certain centers in the selective use of this technique (eg eccentric image of pEBUS). A minimum of 3 and a maxmimum of 5 cryobiopsies will be performed when using the cryoprobe.

The sequence of use of sampling tools will be at the discretion of the endoscopist. Rapid on-site examination (ROSE) may be used, but must be used systematically for every case in both arms of the study at the participating center. Each center will determine before beginning recruitment for the study whether it will use ROSE or not, as for FNA.

If systematic lymph node staging is performed, it will be performed after peripheral EBUS. ROSE may or may not be used for lymph node sampling.

Randomization will be carried out at the end of the first visit to allow the logistical organization of the second visit, which includes the intervention. A 1:1 randomization, stratified for center and the presence of a bronchus sign will be performed. A bronchus sign will be defined by the presence of a bronchus leading directly to the lesion. Randomization will be centralized using the RedCapMD computer platform including a computer-generated randomization table by a consultant statistician. Participating centers will not have access to the randomization table. The participant and the medical team performing the intervention cannot realistically be blinded to the group to which the participant was randomized, but the primary outcome will depend on the impression of the pathologist and physician reviewing the chart who will be blinded to the randomization group. The pathologist will also be blinded to the cryoprobe biopsies when reviewing other biopsies of the same patient (forceps, brush, fine needle and wash) to prevent contamination of his final diagnosis for the other biopsies by the cryoprobe biopsy. The cryoprobe biopsy will be reviewed by a second pathologist or the same pathologist after recording is impression for the other biopsies. At no time before the end of the study can the blinding be lifted for the pathologist or physician reviewing the final diagnosis.

03

Conditions studied

  • Lung Cancers
  • Peripheral Pulmonary Nodules

Browse trials for

Keywords

  • Lung cancer
  • Peripheral pulmonary nodules
  • bronchoscopy
  • peripheral endobronchial ultrasound
  • sedation
04

Who can participate

The criteria were revised on the registry on Nov 9, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years and ability to consent
  • Peripheral lung lesion less than 5cm in average diameter on axial CT images (A lung lesion will be considered peripheral if it is located beyond the origin of the subsegmental bronchi and presumed not to be visible endoscopically in white light during the evaluation of the CT scan by an interventional pulmonologist.)
  • Lesion deemed accessible by pEBUS by an experienced interventional pulmonologist
  • Decision by the medical team and the patient to use pEBUS as a diagnostic modality for the lung lesion

Exclusion criteria

Exclusion Criteria:

  • Presence of multiple lung lesions with sampling of more than one lung lesion planned
  • Planned use of electromagnetic navigation, augmented fluoroscopy or robotic bronchoscopy in addition to pEBUS. The use of virtual bronchoscopy planning is permitted
  • Presence of suspicious lymph nodes (size ≥ 10mm and/or moderate or greater hypermetabolism) on imaging which are accessible by l-EBUS and for which rapid on-site cytological analysis will be used
  • to bronchoscopy or such as an unstable medical condition or uncorrected coagulopathy
  • Current pregnancy or lactation
  • Lack of free and
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
306 participants (estimated)

Study arms

  • Experimental
    Conscious sedation arm

    In the conscious sedation group, the procedure will be performed through the nose or mouth at the discretion of the endoscopist. The patient will remain breathing spontaneously throughout the procedure and will be administered oxygen through a nasal cannula at an initial flow rate of 2L/min. A combination of propofol, fentanyl and midazolam boluses will be used to maintain moderate sedation. At IUCPQ-UL, fentanyl and midazolam will be used as in our routine practice. The boluses will be prescribed by a doctor experienced in conscious sedation (anesthesiologist, intensivist or pulmonologist) according to the patient's state of wakefulness assessed by the Richmond Agitation-Sedation Scale (RASS) .Centers will decide, prior to initiating recruitment locally, the drug combination used to sedate patients and they will maintain the use of the same drug combination throughout the study.

    Procedure: Peripheral EBUS under Concious sedation

  • Experimental
    General anesthesia arm

    In the general anesthesia group, an endotracheal tube larger than 7 will be used. The patient will be kept non-arousable to non-nociceptive stimulation (RASS = -5) by a perfusion including, at the anesthesiologist's discretion: fentanyl, sufentanyl, remifentanyl, midazolam or propofol. The sedation of this group will not be protocolized given the wide variety of practices in the participating centers, but the targeted level of sedation will be and the medication administered will be adjusted according to this target. The RASS will be evaluated every 5 minutes, or earlier if signs of arousal are present, to ensure that the intended target is maintained and adjustments to the rate of infusions as well as boluses may be made/administered by the anesthesiologist to maintain the targeted level of sedation. Patients may be paralyzed at the discretion of the anesthesiologit. The ventilatory parameters will be standardized according to the VESPA protocol

    Procedure: Peripheral EBUS under General Anesthesia

Interventions

  • ProcedurePeripheral EBUS under Concious sedation

    In the conscious sedation group, the procedure will be performed through the nose or mouth at the discretion of the endoscopist. The patient will remain breathing spontaneously throughout the procedure and will be administered oxygen through a nasal cannula at an initial flow rate of 2L/min. A combination of propofol, fentanyl and midazolam boluses will be used to maintain moderate sedation. At IUCPQ-UL, fentanyl and midazolam will be used as in our routine practice. The boluses will be prescribed by a doctor experienced in conscious sedation (anesthesiologist, intensivist or pulmonologist) according to the patient's state of wakefulness assessed by the Richmond Agitation-Sedation Scale (RAS) .Centers will decide, prior to initiating recruitment locally, the drug combination used to sedate patients and they will maintain the use of the same drug combination throughout the study

  • ProcedurePeripheral EBUS under General Anesthesia

    In the general anesthesia group, an endotracheal tube larger than 7 will be used. The patient will be kept non-arousable to non-nociceptive stimulation (RAS = -5) by a perfusion including, at the anesthesiologist's discretion: fentanyl, sufentanyl, remifentanyl, midazolam or propofol. The sedation of this group will not be protocolized given the wide variety of practices in the participating centers, but the targeted level of sedation will be and the medication administered will be adjusted according to this target. The RAS will be evaluated every 5 minutes, or earlier if signs of arousal are present, to ensure that the intended target is maintained and adjustments to the rate of infusions as well as boluses may be made/administered by the anesthesiologist to maintain the targeted level of sedation. Patients may be paralyzed at the discretion of the anesthesiologit. The ventilatory parameters will be standardized according to the VESPA protocol

06

What researchers measure

Primary outcomes

  1. Diagnostic yield of pEBUS under general anesthesia and conscious sedation

    The diagnostic yield of pEBUS according to a strict definition, a procedure being defined as diagnostic if it allows a specific benign or malignant diagnosis using the samples obtained. Non-specific findings not allowing a precise diagnosis and accompanied by a follow-up evolution consistent with the findings (e.g.: non-specific inflammation followed by spontaneous resolution of the lesion) will not be considered diagnostic. Cryobiopies will be excluded from the primary outcome analysis as they may not be performed systematically in both groups. We do not primarly aim to evaluate the added value of cryobiopsy but to compare two modalities of sedation. The comparison between the diagnostic yields for the two types of sedation will be made with a χ2 test, if the distribution of the data is normal

    Time frame: At recruitment completion (expected time 2 years)

Secondary outcomes

  1. Diagnostic yield of pEBUS

    The diagnostic yield of pEBUS according to a strict definition with inclusion of cryobiopsy results. The comparison of the variables will be carried out with a χ2 test

    Time frame: At recruitment completion (expected time 2 years)

  2. Diagnostic yield of pEBUS

    The diagnostic yield of pEBUS according to a strict definition, with and without inclusion of cryobiopsy results, amongst lesions under and over 20mm of average diameter. The comparison of the variables will be carried out with a χ2 test

    Time frame: At recruitment completion (expected time 2 years)

  3. Diagnostic yield of pEBUS

    The diagnostic yield of pEBUS according to a liberal definition, a procedure being defined as diagnostic if it allows a specific benign or malignant diagnosis or if it demonstrates non-specific inflammation and that during follow-up a precise benign diagnosis is established or that the lesion regresses on serial imaging. This analysis will be performed with and without inclusion of cryobiopsies. The comparison of the variables will be carried out with a χ2 test

    Time frame: At recruitment completion (expected time 2 years)

  4. Duration of the procedure

    The duration of the procedure from insertion of the bronchoscope to its removal, excluding the time spent on l-EBUS if applicable

    Time frame: Assessment will begin with the start of the procedure (bronchoscope insertion) and end at procedure completion (bronchoscope removal)

  5. Duration of the procedure

    The duration of the procedure from patient's procedure room entry to his departure from the procedure room.

    Time frame: Assessment will begin when the participant enters the procedure room and end when he leaves it. Result will be recorded when the patient leaves the procedure room.

  6. Recovery duration

    The duration of post-procedure recovery before reaching the criteria for discharge (PADS ≥ 9 and adequate oxygen saturation)

    Time frame: Assessment will begin when the participant leaves the procedure room and end when he is discharged from the recovery room. Result will be recorded when the patient is discharged from the recovery room.

  7. Participant Comfort

    Comfort during the examination according to the patient's answers to two Likert scales of memory of the procedure (absolutely no memory, no specific details, a few details, most of the details, all the details) and willingness to repeat the examination if medically required (definitely not, probably not, uncertain, probably, definitily), and a comfort questionnaire regarding their perception during and after the procedure (dyspnea, cough, pain, anxiety, nausea, general discomfort)

    Time frame: Questionnaires will be administered once the patient is ready for discharge from the recovery room

  8. Adverse event rates

    The rate of adverse events and serious adverse events of pEBUS under general anesthesia versus conscious sedation

    Time frame: At recruitment completion (expected time 2 years)

07

Study locations

2 of 4 sites recruiting
  • Institut universitaire de cardiologie et de pneumologie de Québec
    Québec, Quebec G1V 4G5, Canada
    Recruiting
  • St. Elisabethen Hospital Frankfurt
    Frankfurt am Main, Hesse 60487, Germany
    Not yet recruiting
    • Sammy Onyancha, MD · Contactsammyonyancha@gmail.com · +49 69 79390
    • Sammy Onyancha, MD · Principal investigator
  • Sotiria Thoracic Diseases Hospital of Athens
    Athens, Greece
    Recruiting
    • Grigoris Stratakos, MD,PhD, FCCP · Contactgrstrat@hotmail.com · +30-2107763448
    • Grigoris Stratakos, MD,PhD, FCCP · Principal investigator
  • Hospital Universitario Central de Asturias
    Oviedo, Principality of Asturias, Spain
    Not yet recruiting
    • Miguel Angel Ariza Prota, MD · Contactarizamiguel@hotmail.com · +34 985 10 80 00
    • Miguel Angel Ariza Prota, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Aug 2027, 23 months after the start.

Of 871 non-industry interventional studies with no phase under Lung Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 69. This study's planned 23 months is below that.

Counting every sponsor, half of 922 studies reached it within 34 months; a quarter within 15 and three quarters within 67.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 14, 2025
First posted
Apr 30, 2025
StartActual
Sep 25, 2025
Primary completionEst.
Aug 2027
CompletionEst.
Aug 2029
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites added — first sites in Germany, Greece and Spain
Show 3 added (1 Germany, 1 Greece, 1 Spain)
  • St. Elisabethen Hospital Frankfurt · Frankfurt am Main, Germany
  • Sotiria Thoracic Diseases Hospital of Athens · Athens, Greece
  • Hospital Universitario Central de Asturias · Oviedo, Spain
Nov 9, 2026
Eligibility
1 exclusion criterion edited, 1 added
What changed in the criteria
Exclusion criteria
  • AddedPresence of multiple lung lesions with sampling of more than one lung lesion planned
  • EditedCurrent pregnancy or lactation
Nov 9, 2026
Primary outcomes
1 description edited
What changed in the outcomes
  • DescriptionDiagnostic yield of pEBUS under general anesthesia and conscious sedation: how it is measured was reworded
Nov 9, 2026
Secondary outcomes
1 description edited
What changed in the outcomes
  • DescriptionParticipant Comfort: how it is measured was reworded
Nov 9, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Institut universitaire de cardiologie et de pneumologie de Québec · Québec, CanadaContact added m•••@criucpq.ulaval.ca · •••8711Contact added (no phone or email listed)
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    3 sites added — first sites in Germany, Greece and Spain
    Show 3 added (1 Germany, 1 Greece, 1 Spain)
    • St. Elisabethen Hospital Frankfurt · Frankfurt am Main, Germany
    • Sotiria Thoracic Diseases Hospital of Athens · Athens, Greece
    • Hospital Universitario Central de Asturias · Oviedo, Spain
    Eligibility 1 exclusion criterion edited, 1 added
    What changed in the criteria
    Exclusion criteria
    • AddedPresence of multiple lung lesions with sampling of more than one lung lesion planned
    • EditedCurrent pregnancy or lactation
    Primary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionDiagnostic yield of pEBUS under general anesthesia and conscious sedation: how it is measured was reworded
    Secondary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionParticipant Comfort: how it is measured was reworded
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Institut universitaire de cardiologie et de pneumologie de Québec · Québec, CanadaContact added m•••@criucpq.ulaval.ca · •••8711Contact added (no phone or email listed)
    + 3 other changes: verification date, description and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06950515
Lead sponsor
Institut universitaire de cardiologie et de pneumologie de Québec, University Laval
Responsible party
Marc Fortin (Principal Investigator, Institut universitaire de cardiologie et de pneumologie de Québec, University Laval) — Principal investigator
First posted
Apr 30, 2025
Start date
Sep 25, 2025
Primary completion
Aug 2027 (estimated)
Completion
Aug 2029 (estimated)
Last update
Nov 9, 2026

Study contacts

Marc Fortin, MD
Contact
marc.fortin@criucpq.ulaval.ca
418-656-8711 ext. 5504

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion